Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1921973 | 0.97 | ALDH1A1 (0.47) | ALDH1A1USP2SMN1; SMN2 | |
| Tetrahydrofuran SCHEMBL28159237 | 0.97 | ALDH1A1 (0.47) | ALDH1A1USP2SMN1; SMN2 | |
| Dioxane SCHEMBL1921978 | 0.87 | ALDH1A1 (0.57) | ALDH1A1USP2SMN1; SMN2 | |
| SCHEMBL1921976 | 0.81 | ALDH1A1 (0.50) | ALDH1A1 | |
| Tetrahydrofuran SCHEMBL2041223 | 0.79 | — | — | |
| Tetrahydrofuran SCHEMBL2514312 | 0.79 | ALDH1A1 (0.47) | ALDH1A1USP2SMN1; SMN2 | |
| Tetrahydrofuran SCHEMBL8787962 | 0.79 | ALDH1A1 (0.47) | ALDH1A1USP2SMN1; SMN2 | |
| Tetrahydrofuran SCHEMBL8787966 | 0.77 | ALDH1A1 (0.44) | ALDH1A1USP2SMN1; SMN2 | |
| Methoxymethane SCHEMBL9829152 | 0.76 | — | — | |
| Tetrahydrofuran SCHEMBL28446839 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117887031-A | High molecular weight high biosafety sulfonamide polymer and preparation method thereof | 智元柏迈(杭州)科技有限公司 | 2024-04-16 | — | — | CN | claimed |
| WO-2024046279-A1 | POLYMORPH OF MAO-B INHIBITOR PRODRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 广州市恒诺康医药科技有限公司 | 2024-03-07 | — | — | WO | claimed |
| CN-117623989-A | Polymorphic form of MAO-B inhibitor prodrug, and preparation method and application thereof | 广州市恒诺康医药科技有限公司 | 2024-03-01 | — | — | CN | claimed |
| CN-115397426-B | Ebutinib glucolactone co-crystal and preparation method thereof | 天津睿创康泰生物技术有限公司 | 2024-02-09 | — | — | CN | claimed |
| CN-115397426-A | Ibutotinib glucolactone eutectic and preparation method thereof | 天津睿创康泰生物技术有限公司 | 2022-11-25 | — | — | CN | claimed |
| CN-115385918-A | Novel midazolam crystal form and preparation method thereof | 成都硕德药业有限公司 | 2022-11-25 | — | — | CN | claimed |
| CN-115197075-A | Preparation method of efavirenz key intermediate | 盐城迪赛诺制药有限公司 | 2022-10-18 | — | — | CN | claimed |
| CN-113968791-A | Preparation method of efavirenz key intermediate | 盐城迪赛诺制药有限公司 | 2022-01-25 | — | — | CN | claimed |
| CN-113387944-B | Synthetic method of rosuvastatin calcium intermediate | 浙江宏元药业股份有限公司 | 2021-12-28 | — | — | CN | claimed |
| US-20210347736-A1 | CRYSTALLINE FORMS OF A FARNESOID X RECEPTOR AGONIST | METACRINE, INC. | 2021-11-11 | — | — | US | claimed |
| US-20120115890-A1 | SOLID FORMS COMPRISING 4-[9-(TETRAHYDRO-FURAN-3-YL)-8-(2,4,6-TRIFLUORO-PHENYLAMINO)-9H-PURIN-2-YLAMINO]-CYCLOHEXAN-1-OL, COMPOSITIONS THEREOF, AND USES THEREWITH | BEAUCHAMPS MARIE G (US) | 2012-05-10 | — | — | US | claimed |
| WO-2009060318-A2 | POLYMORPHIC FORMS OF RAMELTEON AND PROCESSES FOR PREPARATION THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-05-14 | — | — | WO | claimed |
| US-20090105490-A1 | Polymorphic forms of ramelteon and processes for preparation thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-04-23 | — | — | US | claimed |
| US-20090069593-A1 | intermediates for synthesis of (S)-Pregabalin; anticonvulsants; crystalline form | KANSAL VINOD KUMAR | 2009-03-12 | — | — | US | claimed |
| EP-1863761-A1 | PROCESS FOR PREPARING LEVETIRACETAM | Rubamin Limited (IN) | 2007-12-12 | — | — | EP | claimed |
| EP-1841726-A1 | AN ASYMMETRIC SYNTHESIS OF ( S ) - ( + ) -3- (AMINOMETHYL) -5-METHYLHEXANOIC ACID | Teva Pharmaceutical Industries Ltd (IL) | 2007-10-10 | — | — | EP | claimed |
| US-20070197827-A1 | Novel asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-23 | — | — | US | claimed |
| WO-2007035890-A1 | AN ASYMMETRIC SYNTHESIS OF ( S ) - ( + ) -3- (AMINOMETHYL) -5-METHYLHEXANOIC ACID | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-03-29 | — | — | WO | claimed |
| WO-2006095362-A1 | PROCESS FOR PREPARING LEVETIRACETAM | RUBAMIN LIMITED (IN) | 2006-09-14 | — | — | WO | claimed |
| US-4900477-A | Novel intermediates and an improved process for producing the compound (3β,5α)-3-hydroxycholest-8(14)-en-15-one | AMERICAN CYANAMID COMPANY (US) | 1990-02-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105490-A1 | Polymorphic forms of ramelteon and processes for preparation thereof | CYP2D6, CYP2B6, CYP3A43 | ALDH1A1 2850/4885USP2 3623/4885SMN1; SMN2 2457/4885 |
| US-20070197827-A1 | Novel asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid | RIMKLA, COASY, GABRE | ALDH1A1 956/4885USP2 1113/4885SMN1; SMN2 3043/4885 |
| US-20090069593-A1 | intermediates for synthesis of (S)-Pregabalin; anticonvulsants; crystalline form | GABRE, GABRA5, GABRA6 | ALDH1A1 1019/4885USP2 2557/4885SMN1; SMN2 3238/4885 |
| US-20120115890-A1 | SOLID FORMS COMPRISING 4-[9-(TETRAHYDRO-FURAN-3-YL)-8-(2,4,6-TRIFLUORO-PHENYLAMINO)-9H-PURIN-2-YLAMINO]-CYCLOHEXAN-1-OL, COMPOSITIONS THEREOF, AND USES THEREWITH | PYGL, OAT, VHL | ALDH1A1 405/4885USP2 3624/4885SMN1; SMN2 91/4885 |
| US-20210347736-A1 | CRYSTALLINE FORMS OF A FARNESOID X RECEPTOR AGONIST | NR1H4, NR1H3, NR1H2 | ALDH1A1 3555/4885USP2 4033/4885SMN1; SMN2 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.